The rise in direct-to-patient therapeutics access via online compounding pharmacies and other direct-to-patient sales models has increased the likelihood of patients utilizing medications alongside ...

Urban mobility in major metro areas operates at a scale where traditional transportation management approaches begin to fail.

This story has been updated with additional comments from Datavant. Health tech company Datavant is making moves to be a bigger player in the real-world data space. The company announced Thursday that ...

Thanks to new regulatory frameworks like the Food and Drug Administration’s Breakthrough Therapy designation, drugs are coming to market faster than ever. A 2024 analysis of drugs included in this ...

NovaBuilder is an open-source, self-hosted internal tool builder designed for building and operating real-world business ...

Knowing patient survival rates is critical to informing research and care delivery, particularly in the oncology space. But what if survival data is inaccurate or incomplete? Well, that could ...

Jeffrey Stark, MD, vice president, head of medical immunology, UCB, discusses ongoing clinical trials and the development of real-world data to understand the effectiveness of bimekizumab-bkzx in a ...

For manufacturers, building a static commercialization strategy will only take you so far. But infusing that strategy with real-world data (RWD) — consisting of medical claims, lab testing and ...

Outside of tightly controlled environments, most robotic systems still struggle with reliability, generalization and cost. The gap between what we can demonstrate and what we can operate at scale ...

Delayed IPF diagnosis often results in significant lung function impairment, impacting patient outcomes and increasing hospitalization rates. Antifibrotic therapies, nintedanib and pirfenidone, are ...

The Tesla Semi has been a long-running project for the electric automaker. As is the Tesla way, the company has promised big things long ahead of the product actually reaching the market. Now, we’re ...